Active Biotech AB

Active Biotech Secures US Patent for Tasquinimod Formulation, Extending Market Exclusivity to 2042

- Active Biotech announced that the US Patent and Trademark Office will grant patent number 12,485,095 for a pharmaceutical formulation of tasquinimod on December 2, 2025. - The patent provides market exclusivity protection until 2042 and relates to a formulation with high oral bioavailability for the immunomodulatory drug. - Tasquinimod has received FDA orphan drug status for treating myelofibrosis and multiple myeloma, with Active Biotech focusing development on rare blood cancers. - The patent grant strengthens the company's multi-layer intellectual property strategy for tasquinimod, which is covered by multiple patents for medical use in relevant indications.